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Purpose: Results from 2 patient-reported outcome studies of allergic conjunctivitis sufferers 
who used olopatadine 0.2% and azelastine 0.05% are analyzed.
Methods: The PACE (Pataday Allergic Conjunctivitis Evaluation) multi-center, prospective, 
open-label study examined patient perceptions of olopatadine 0.2% once daily (qd) and previous 
twice daily (bid) allergic conjunctivitis medications via questionnaire in allergic conjunctivitis 
sufferers who had previously used bid medication and then initiated olopatadine. A second 
conjunctival antigen challenge (CAC) study evaluated comfort of 4 allergic conjunctivitis 
medications.
Results: Forty-nine patients from the PACE study (N = 125) with prior azelastine use 
were examined. Signiﬁ  cantly more patients rated themselves “very satisﬁ  ed” with current 
olopatadine use compared with past azelastine use on drop comfort (p  0.0001), speed of relief 
(p = 0.0004), and overall satisfaction (70% vs 16%, p  0.0001). Signiﬁ  cantly more patients 
reported olopatadine “very effective” against swelling compared with azelastine (47% vs 8%, 
p = 0.0404). In the CAC study (N = 36), data from olopatadine (n = 8), azelastine (n = 9) and 
placebo (N = 36) groups were reported. Olopatadine was rated signiﬁ  cantly more comfortable 
than azelastine upon instillation (p = 0.0223), at 30 seconds (p = 0.0479), and at 1 minute after 
instillation (p = 0.0240).
Conclusion: In the reported studies, olopatadine 0.2% qd was more comfortable than azelastine 
0.05% and preferred by patients with allergic conjunctivitis by a ratio of 4:1.
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Introduction
Allergic conjunctivitis is a complex disorder that signiﬁ  cantly contributes to the burden 
of misery and economic impact resulting from environmental allergies, especially in 
those patients who are either untreated or ineffectively treated.1 Allergic conjunctivitis 
is reported to affect approximately 15% to 20% of the US population.2 Some suggest 
that as much as 30% of the US population is affected by seasonal allergy symptoms 
with as many as 70% to 80% of these people having ocular symptoms.3 Recent reports 
suggest that ocular allergy is both under-diagnosed and under-treated; therefore, 
the actual global impact may be underrepresented.4 Seasonal and perennial allergic 
rhinitis and conjunctivitis cause disruption in daily activities, which is reﬂ  ected by 
diminished quality of life measures.1,5 Managing allergy effectively requires adequate 
relief of symptoms and prevention of future symptoms. With this approach, patients 
have reported enhanced quality of life.1,6
The ocular manifestations of seasonal and perennial allergy occur as a result of mast 
cell degranulation and subsequent allergic inﬂ  ammation in sensitized individuals. During Clinical Ophthalmology 2009:3 330
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this cascade, allergens bind and cross-link allergen-speciﬁ  c 
IgE antibodies on conjunctival mast cell surfaces, initiating 
degranulation and the release of histamine. Once released, 
histamine binds to histamine receptors on the conjunctival 
surface, causing itching, redness, and swelling.7 Recent 
evidence suggests that histamine-stimulated conjunctival 
epithelial cells may upregulate the allergic inﬂ  ammatory 
cascade.8,9 Mast cells additionally release both preformed 
and synthesized mediators that contribute to the allergic 
response.10,11
The comparatively large surface area of the conjunctiva, 
a robust vascular supply, and a dense concentration of mast 
cells make allergic conjunctivitis a particularly vexing 
form of allergy for affected patients. As such, appropriate 
diagnosis and effective treatment can have a positive impact 
on patient’s quality of life and disease management. In 
addition, meeting a patient’s perceived needs is paramount 
for effective allergy management, particularly with ocular 
allergy, due to the eyes’ habitual but necessary exposure to 
the environment.
The newest class of topical anti-allergy medication 
for allergic conjunctivitis is the dual-action agent, which 
combines strong antihistaminic activity (providing rapid 
relief) with mast-cell stabilizing properties (responsible 
for prolonged relief).12 Five dual-action agents have earned 
approval from the US Food and Drug Administration (FDA) 
for the treatment of allergic conjunctivitis: epinastine 0.05% 
(Elestat®; Allergan, Inc., Irvine, CA, USA), ketotifen 0.025% 
(Zaditor®; Novartis Ophthalmics, Duluth, GA, USA), 
azelastine 0.05% (Optivar®; MedPointe Pharmaceuticals, 
Somerset, NJ, USA), olopatadine 0.1% (Patanol®; Alcon 
Laboratories, Inc., Fort Worth, TX, USA), and olopatadine 
0.2% (Pataday™; Alcon Laboratories, Inc., Fort Worth, 
TX, USA).
Despite similar classiﬁ  cation, there is evidence that sig-
niﬁ  cant differences exist between the various agents. Speciﬁ  -
cally, olopatadine 0.1%, the ﬁ  rst dual-action agent approved 
by the FDA, has demonstrated superior efﬁ  cacy compared to 
the other dual-action agents in numerous clinical studies.13–15  
Olopatadine also demonstrates minimal surface activity on 
mast cell and corneal epithelial cell membranes, which is 
dose-dependent and potentially clinically relevant.16 As the 
ﬁ  rst agent in its class, olopatadine 0.1% has become the agent 
by which all other agents in this class are judged.
Olopatadine 0.2% was recently introduced in an attempt 
to improve on the qualities of the 0.1% formulation. It 
has demonstrated patient acceptance and clinical efﬁ  cacy 
comparable or superior to olopatadine 0.1%.17 Like other 
dual-action agents, olopatadine 0.2% is approved for the 
treatment of itching associated with allergic conjunctivitis.18 
However, it is the only dual-action agent to be indicated for 
once daily (qd) dosing,18 providing a potential advantage 
over twice daily (bid) medications.19–22 Once daily dosing 
provides increased convenience and possibly even improved 
patient adherence to treatment. With more convenient qd 
dosing, it is likely that olopatadine 0.2% will supplant its 
lower concentration predecessor.23
Olopatadine 0.2% has demonstrated superior comfort and 
efﬁ  cacy compared to the dual-action agent epinastine 0.05%.24 
No controlled clinical studies have been published directly 
comparing olopatadine 0.2% and azelastine 0.05%; however, 
olopatadine 0.1% has demonstrated superior clinical efﬁ  cacy 
compared to azelastine 0.05% in a comparison using the 
controlled conjunctival antigen challenge (CAC) model.15
To examine the relative clinical characteristics of 
olopatadine 0.2% and azelastine 0.05%, this report 
explores the relationship among clinical efﬁ  cacy, perceived 
comfort and therapeutic satisfaction of these 2 agents. 
Speciﬁ  cally, selected results from 2 independent, prospective, 
patient-reported outcome studies focusing on allergic 
conjunctivitis management using either or both olopatadine 
0.2% and azelastine 0.05% are examined to gain insight into 
this clinically important paradigm.25,26
Methods
PACE study
The PACE (Pataday Allergic Conjunctivitis Evaluation) 
study was a multi-center, prospective, open-label, single-arm 
study conducted at 10 allergy, ophthalmology, and optometry 
practices throughout the US during the spring of 2008 that 
examined adult patients with allergic conjunctivitis. The 
purpose of this study was to evaluate patient perceptions of 
olopatadine 0.2% and previous bid anti-allergy medication 
(olopatadine 0.1%, azelastine 0.05%, ketotifen 0.025%, or 
epinastine 0.05% used within the last 6 months) for the treat-
ment of allergic conjunctivitis. This report presents data only 
from those patients in the azelastine 0.05% group.
Patients 18 years or older with active signs and/or 
symptoms of allergic conjunctivitis (as assessed by the 
investigator) who had been treated in the last 6 months with a 
prescription, topical, ocular, anti-allergy, bid medication were 
included in this study. Exclusion criteria were any serious 
ocular or other medical condition that could result in a patient’s 
inability to safely complete the study; hypersensitivity or 
other contraindication to the use of the study medication or 
its components; known history of recurrent corneal erosion Clinical Ophthalmology 2009:3 331
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syndrome; ocular trauma in either eye within 3 months prior 
to Visit 1; any ocular surgical intervention within 6 months 
prior to Visit 1 or anticipation of ocular surgery during the 
study; presumed or actual ocular infection or history of ocular 
herpes in either eye; and any signiﬁ  cant illness that could be 
expected to interfere with the study, including autoimmune 
disease, psoriasis, eczema, rosacea, severe cardiovascular 
disease, poorly controlled hypertension, poorly controlled 
diabetes, history of status asthmaticus, or history of moderate 
to severe allergic asthma.
On Day 1 (Visit 1), patients completed an allergy 
questionnaire to evaluate their previous bid medication and 
investigators completed a medical history. Patients were then 
instructed to begin using qd olopatadine 0.2%. On Day 7, 
patients completed a similar allergy questionnaire to evaluate 
olopatadine 0.2%. Investigators noted any adverse events or 
changes in concomitant medication at that time.
The questionnaires asked patients to rate their perceptions 
of efﬁ  cacy for their anti-allergy medication (previous bid 
medication was rated at Day 1 and olopatadine 0.2% at Day 7) 
with respect to ocular itching, redness, tearing, and swelling 
using the 5 descriptors: very/somewhat effective, undecided, 
and very/somewhat ineffective. Patients were also asked to 
rate their satisfaction with their anti-allergy medication with 
respect to 3 parameters (drop comfort, speed of relief, and 
overall satisfaction) using the descriptors: very/somewhat 
satisﬁ  ed, undecided, and very/somewhat dissatisﬁ  ed. Within-
patient changes from baseline to follow-up in the global score 
were tested using paired t test. Between-group comparisons 
were carried out using Pearson’s chi square test, or Fisher’s 
exact test when sample sizes 30. A p value of  0.05 was 
considered statistically signiﬁ  cant. Statistical analysis was 
performed in SAS (PC Version 9.1.2, SAS Institute, Cary, 
NC, USA) by an independent biostatistician. Safety was 
assessed via collection of all reported adverse events.
Conjunctival antigen challenge study
This was a single-center, prospective, double-masked, 
placebo- and contralaterally controlled CAC study of 
patients with a documented history of allergic conjuncti-
vitis conducted by Ophthalmic Research Associates, Inc. 
(North Andover, MA, USA) January to February 2007. The 
purpose of this CAC study was to determine the comfort of 
qd olopatadine 0.2% relative to currently available bid anti-
allergy medications.
Patients 18 years or older must have manifested a positive 
allergen challenge reaction (ie, itching and redness) in each 
eye at both Visit 1 (screening visit) and Visit 2 (conﬁ  rmatory 
visit), manifested a positive skin test reaction within the past 
24 months to the allergen reportedly causing the allergic con-
junctivitis, and had a best-corrected logMAR visual acuity 
score of 0.60 or better in each eye. Exclusion criteria included 
any allergy or contraindication to the use of any study medi-
cation, active ocular infection, any ocular or medical condi-
tion that could affect study parameters, signs or symptoms of 
allergic conjunctivitis (greater than 1+ redness or any itching) 
in either eye at the start of any visit, dry eye syndrome requir-
ing daily use of artiﬁ  cial tear substitute, history of ocular 
surgery within the past 3 months, use of an investigational 
drug or device within 30 days before Visit 1 or during the 
study period, and use of any medications (ie, H1-antagonist 
antihistamines, mast cell stabilizers, corticosteroids) within 
72 hours before Visit 1 or anytime during the study that could 
interfere with the study parameters.
This study followed a standardized CAC protocol.27 
After identifying and conﬁ  rming the proper dosage of a 
known allergen at Visits 1 and 2, patients were randomized 
by treatment and by eye to receive 1 of 4 study medications 
(olopatadine 0.2%, olopatadine 0.1%, azelastine 0.05%, or 
ketotifen 0.025%) in 1 eye. All patients received placebo 
(Tears Naturale II®, Alcon Laboratories, Inc., Fort Worth, 
TX, USA) in the contralateral eye. This report presents data 
only from those eyes treated with olopatadine 0.2%, azelas-
tine 0.05%, or placebo. At Visit 3, investigators instilled 
study medication (anti-allergy medication in one eye and 
placebo in the other) 5 minutes prior to and 30 minutes 
after CAC. Patients assessed drop comfort using an 11-point 
scale (0 = very comfortable to 10 = very uncomfortable) 
immediately, 30 seconds, 1 minute, and 2 minutes after 
second instillation. Differences in mean drop comfort scores 
between treatment groups were assessed using a paired t test 
at each time point. Safety variables assessed were corrected 
distance visual acuity, slit lamp biomicroscopy, and all 
adverse events (reported, elicited, and observed).
Results
PACE study
A total of 125 patients was enrolled in the PACE study.25 
This report presents data from the 49 patients with a history 
of using the bid medication azelastine 0.05%. Forty-eight 
patients (98%) completed the questionnaire at both Day 1 
and Day 7; one patient was lost to follow-up. The average 
age of the 49 patients with a history of azelastine 0.05% 
use was 56.6 years (range, 26–85; Table 1). Approximately 
three-quarters of the patients were female; 51% were white 
and 24% were Hispanic.Clinical Ophthalmology 2009:3 332
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Similar percentages of patients rated olopatadine 
0.2% and azelastine 0.05% as “somewhat effective” for 
both itching and redness, but more patients reported that 
olopatadine was “very effective” compared with azelastine 
0.05% (46% vs 20% for itching, 42% vs 17% for redness; 
Figure 1). While patients reported similar overall favorable 
results (somewhat to very effective) between the 2 medica-
tions for tearing and swelling, more of these patients reported 
that olopatadine 0.2% was “very effective” compared with 
azelastine 0.05% (25% vs 9% for tearing, 47% vs 8% for 
swelling; Figure 2). The difference between medications in 
relief of swelling was statistically signiﬁ  cant (p = 0.0404); 
a trend toward superiority for olopatadine was reported for 
both itching (p = 0.0691) and redness (p = 0.0715).
Approximately 3 to 4 times as many patients rated 
themselves “very satisﬁ  ed” with current olopatadine 0.2% 
use compared with past azelastine 0.05% use on 3 differ-
ent parameters (Figure 3): drop comfort (75% vs 25%, 
p  0.0001), speed of relief (60% vs 20%, p = 0.0004), and 
overall satisfaction (70% vs 16%, p  0.0001).
Among patients who had used azelastine 0.05%, 5 adverse 
events in 3 patients were reported during olopatadine 0.2% 
treatment: adverse taste (n = 2), dry eye (n = 1), post-nasal 
drip (n = 1), and dilated pupil (n = 1). All adverse events 
resolved without treatment.
Conjunctival antigen challenge study
Thirty-six patients were enrolled in the CAC study;26 data 
from 17 eyes included in the olopatadine 0.2% (n = 8) and 
azelastine 0.05% (n = 9) groups and all 36 contralateral 
eyes included in the placebo groups are reported here. Upon 
instillation, olopatadine 0.2% was rated signiﬁ  cantly more 
comfortable than azelastine 0.05% (mean comfort score, 
2.8 vs 7.6, p = 0.0223) and was indistinguishable from that 
of placebo (mean comfort score, 2.8; Figure 4). Patients using 
olopatadine 0.2% also reported signiﬁ  cantly better comfort 
scores than patients using azelastine 0.05% at both 30 seconds 
Table 1 Patient demographics (N = 49)
Age (years)
 Mean  ± SD 56.57 ± 15.62
 Range 26–85
Gender (%)
 Male 26%
 Female 74%
Race (%)
 White 51%
 Black 12%
 Asian 8%
 Hawaiian 4%
 Hispanic 24%
Note: Age information was not available in 1 patient; gender information was not 
available for 2 patients.
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Figure 2 Patient perceptions of tearing and swelling (PACE study).
(p = 0.0479) and 1 minute (p = 0.0240); although olopatadine 
0.2% was numerically better at 2 minutes, this did not reach 
statistical signiﬁ  cance (p = 0.2984). Safety measures were 
not assessed in this CAC study.
Discussion
Allergy is a well-recognized and very common life disruptor. 
Ocular allergy is often overlooked but represents a signiﬁ  -
cant component of the burden of allergic disease for many 
patients.4 The eye is an organ critical for survival yet is 
directly exposed to the environment and offending allergens. 
As such, managing ocular allergy can pose a signiﬁ  cant 
therapeutic challenge. Previous studies have shown supe-
rior targeting and greater effectiveness of topical treatment 
compared with systemic therapies in managing ocular 
allergies.28 This analysis compares 2 currently available 
dual-action topical ocular anti-allergy agents in an attempt to 
better understand what constitutes therapeutic success from 
the patient’s perspective.
Results from these 2 independent studies reinforce the 
importance of comfort and perceived clinical efﬁ  cacy in 
overall patient satisfaction with therapy. Olopatadine 0.2% 
demonstrates superior tolerability compared to azelastine 
0.05% in both studies, with signiﬁ  cantly greater comfort 
upon instillation. In addition, patients from the PACE study 
consistently rated olopatadine 0.2% more favorably in the 
efﬁ  cacy endpoints of itching, redness, tearing, and swelling, 
although swelling was the only efﬁ  cacy parameter to reach 
statistical signiﬁ  cance. Patients from this study also reported 
an increase in overall satisfaction with olopatadine 0.2%. 
Greater efﬁ  cacy and tolerability likely play a role in the 
increased satisfaction with olopatadine 0.2% of patients with 
allergic conjunctivitis.29
Although olopatadine 0.1%, the original bid formulation, 
had been previously judged to be signiﬁ  cantly more comfort-
able than azelastine 0.05% in a randomized, double-masked, 
crossover study of 91 patients with allergic conjunctivitis,30 
the increased concentration of olopatadine 0.2% makes 
tolerability a valid question. However, the current studies 
demonstrate that the comfort of this compound relative to 
azelastine is maintained even at the higher concentration, 
showing 3 times as many patients who were “very satisﬁ  ed” 
with olopatadine’s drop comfort compared with azelastine 
0.05% (75% vs 25%, PACE study). These results are 
supported by results from a patient perception study in which 
patients who had used both olopatadine 0.1% and 0.2% rated 
them equally comfortable.17
The reasons for the superior comfort of olopatadine 
0.2% compared with azelastine 0.05% have not been clearly 
deﬁ  ned, but they may be at least partly attributed to pH Clinical Ophthalmology 2009:3 334
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differences; azelastine 0.05% has a more acidic pH, ranging 
from 5.0 to 6.5,21 whereas olopatadine 0.2% has a physiologic 
pH of approximately 7.18 Another possible explanation for the 
greater comfort of olopatadine may arise from the differing 
effects of these drugs on cell membrane integrity; unlike 
azelastine and other dual-action agents, olopatadine does 
not perturb the membranes of ocular surface epithelial cells, 
the damage of which may explain the stinging and burning 
that can be encountered upon instillation of dual-action 
agents.16
The patient-reported results from the PACE study, showing 
a clear advantage of current olopatadine 0.2% use over past 
azelastine 0.05% use for swelling and a numeric trend toward 
superiority for itching and redness, are consistent with the 
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investigator-reported efﬁ  cacy results from the well-controlled 
CAC study published by Spangler and colleagues.15 This study 
established the clinical superiority of the 0.1% formulation of 
olopatadine over azelastine. Increasing the concentration of 
olopatadine in the 0.2% formulation would not be expected 
to have a negative impact on efﬁ  cacy.
Both of the studies presented here have limitations. The 
conclusions from the PACE study are limited by its nonran-
domized, open-label, single-arm design. Because patients 
may have used their bid medications as much as 6 months 
prior to taking the Day 1 allergy questionnaire, patients had 
to rely on memory, which may have introduced bias. It is 
also possible that patients might have expected the “new” 
medication (olopatadine 0.2%) to be superior to the previous 
medication (azelastine 0.05%), despite being provided with 
no information regarding the efﬁ  cacy of olopatadine 0.2%. 
Although the CAC study had a randomized, double-masked, 
controlled trial design, its small size limits its conclusions as 
well. These confounding variables should be considered when 
deciding which medications to use in the clinical setting.
Conclusion
Allergic conjunctivitis is an under-diagnosed and often 
suboptimally treated component of allergic disease. Although 
currently available ophthalmic medications have facilitated 
the management of this common malady, clinically sig-
niﬁ  cant differences among these agents have been reported 
in the literature.13–15 Effective therapy requires in-depth 
understanding of patient perceptions and responses to these 
therapeutic agents.
This exploration of data from 2 independent studies 
provides insight into the therapeutic dynamic for successfully 
managing ocular allergy by comparing 2 agents of the 
same class that have different clinical performance and 
patient-perceived qualities. Among the patients in these 
2 studies, olopatadine 0.2% dosed once daily proved more 
comfortable and was perceived as clinically more efﬁ  cacious 
than azelastine 0.05%. Patient perception is critically impor-
tant in ensuring sustained compliance and overall satisfaction 
with both the treatment and the provider.
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